文献速递生殖医学

从分娩到后续辅助生殖治疗周期的间隔缩短与临床妊娠率和活产率降低相关

Decreased clinical pregnancy and live birth rates after short interval from delivery to subsequent assisted reproductive treatment cycle.
PubMed 文献 · Hum Reprod · 2018-01-01

基于SART CORS 2004至2013年61 686个ART周期的回顾性分析,计算分娩至周期启动间隔(DCI)。与DCI 12至<18个月相比,DCI<6个月或≥24个月均与临床妊娠和活产概率降低相关。

要点

  • DCI<6个月与临床妊娠和活产概率降低相关。
  • DCI≥24个月同样与临床妊娠和活产概率降低相关。
  • 自然妊娠的生育间隔建议可能不适用于不孕人群。

核心结论

  • DCI<6个月或≥24个月与临床妊娠和活产概率降低相关。
  • 作者建议有活产史并计划ART治疗的患者等待至少6个月但不超过24个月以优化结局。

研究设计与样本

  • 回顾性分析SART CORS队列,纳入2004至2013年61 686个ART周期。
  • 纳入有ART活产史并返回同一诊所进行首次后续治疗周期的患者。
  • 采用广义线性模型评估DCI与临床妊娠和活产风险的关系并生成预测概率。

主要发现

  • DCI<6个月较12至<18个月每周期启动的临床妊娠概率降低5.6%(40.1±1.9% vs 45.7±0.6%,P=0.009)。
  • DCI<6个月较12至<18个月每周期启动的活产概率降低6.8%(31.6±1.7% vs 38.4±0.6%,P=0.001)。
  • DCI≥24个月较12至<18个月的临床妊娠概率降低5.1%(40.6±0.5% vs 45.7±0.6%,P<0.001)。
  • DCI≥24个月较12至<18个月的活产概率降低5.7%(32.7±0.5% vs 38.4±0.6%,P<0.001)。

临床怎么用

  • 作者建议计划ART治疗的患者从活产起等待至少6个月但不超过24个月。
  • 作者认为自然妊娠人群的生育间隔建议可能不普遍适用于不孕患者。

局限性

  • SART数据库依赖包括活产在内的许多变量的自我报告。
  • 尚不清楚较差结局是源于DCI极短或极长人群固有因素的残余混杂还是间隔本身。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the interval from delivery to initiation of a subsequent ART treatment cycle impact clinical pregnancy or live birth rates? SUMMARY ANSWER: An interval from delivery to treatment start of <6 months or ≥24 months is associated with decreased likelihood of clinical pregnancy and live birth. WHAT IS KNOWN ALREADY: Short interpregnancy intervals are associated with poor obstetric outcomes in the naturally conceiving population prompting birth spacing recommendations of 18-24 months from international organizations. Deferring a subsequent pregnancy attempt means a woman will age in the interval with an attendant decline in her fertility. STUDY DESIGN, SIZE, DURATION: Retrospective analysis of the Society for Assisted Reproductive Technology Clinical Outcome Reporting System (SARTCORS) cohort containing 61 686 ART cycles from 2004 to 2013. PARTICIPANTS/MATERIALS, SETTING, METHODS: The delivery-to-cycle interval (DCI) was calculated for patients from SARTCORS with a history of live birth from ART who returned to the same clinic for a first subsequent treatment cycle. Generalized linear models were fit to determine the risk of clinical pregnancy and live birth by DCI with subsequent adjustment for factors associated with outcomes of interest. Predicted probabilities of clinical pregnancy and live birth were generated from each model. MAIN RESULTS AND THE ROLE OF CHANCE: A DCI of <6 months was associated with a 5.6% reduction in probability of clinical pregnancy (40.1 ± 1.9 versus 45.7 ± 0.6%, P = 0.009) and 6.8% reduction in live birth (31.6 ± 1.7 versus 38.4 ± 0.6%, P = 0.001) per cycle start compared to a DCI of 12 to <18 months. A DCI of ≥24 months was associated with a 5.1% reduction in probability of clinical pregnancy (40.6 ± 0.5 versus 45.7 ± 0.6%, P < 0.001) and 5.7% reduction in live birth (32.7 ± 0.5 versus 38.4 ± 0.6%, P < 0.001) compared to 12 to <18 months. LIMITATIONS, REASONS FOR CAUTION: The SART database is reliant upon self-report of many variables of interest including live birth. It remains unclear whether poorer outcomes are a result of residual confounding from factors inherent to the population with a very short or long DCI or the interval itself. WIDER IMPLICATIONS OF THE FINDINGS: Birth spacing recommendations for naturally conceiving populations may not be generally applicable to patients with a history of infertility. Patients planning ART treatment should wait a minimum of 6 months, but not more than 24 months, from a live birth for optimization of clinical pregnancy and live birth rates. STUDY FUNDING/COMPETING INTEREST(S): National Center for Advancing Translational Sciences, National Institutes of Health, UCSF-CTSI Grant number UL1TR001872. The authors have no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Quinn MM, Rosen MP, Allen IE, et al. Decreased clinical pregnancy and live birth rates after short interval from delivery to subsequent assisted reproductive treatment cycle. Hum Reprod. 2018. PMID: 29912323. doi:10.1093/humrep/dey108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。